ReviewCancers2026
Differences in Somatic Mutations Between Early-Onset and Late-Onset Colorectal Cancer: A Systematic Review and Meta-Analysis.
Review in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEarly-onset colorectal cancer (EOCRC, diagnosed <50 years) is increasing globally and presents with advanced clinicopathological features, yet its mutational landscape compared to late-onset CRC (LOCRC) remains poorly defined.
methodsWe systematically searched PubMed and Embase (January 2016-December 2025) for studies comparing somatic mutations between EOCRC and LOCRC. Two reviewers independently screened 1880 records; 43 studies met inclusion criteria. Two public datasets (TCGA, China PanCancer) were also included. Meta-analyses were conducted using random-effects models with Review Manager. Subgroup analysis was restricted to microsatellite-stable (MSS) tumors. Meta-regression evaluated study-level differences in tumor sidedness and stage distribution as sources of heterogeneity. The primary outcome was odds ratios (OR) for mutations in 10 driver genes.
resultsAmong 154,982 participants, 33,937 (21.9%) had EOCRC. In the overall analysis, EOCRC showed higher frequencies of
conclusionsEOCRC exhibits a different mutational profile with higher
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.